Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.
Mazzotta M, Filetti M, Occhipinti M, Marinelli D, Scalera S, Terrenato I, Sperati F, Pallocca M, Rizzo F, Gelibter A, Botticelli A, Scafetta G, Di Napoli A, Krasniqi E, Pizzuti L, Barba M, Carpano S, Vici P, Fanciulli M, De Nicola F, Ciuffreda L, Goeman F, De Maria R, Vecchione A, Giusti R, Ciliberto G, Marchetti P, Maugeri-Saccà M. Mazzotta M, et al. Among authors: gelibter a. J Immunother Cancer. 2020 Aug;8(2):e000946. doi: 10.1136/jitc-2020-000946. J Immunother Cancer. 2020. PMID: 32759236 Free PMC article.
Emerging pathways and future targets for the molecular therapy of pancreatic cancer.
Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M. Vaccaro V, et al. Among authors: gelibter a. Expert Opin Ther Targets. 2011 Oct;15(10):1183-96. doi: 10.1517/14728222.2011.607438. Epub 2011 Aug 7. Expert Opin Ther Targets. 2011. PMID: 21819318 Review.
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M. Vari S, et al. Among authors: gelibter a. Expert Opin Drug Discov. 2013 Nov;8(11):1381-97. doi: 10.1517/17460441.2013.843523. Epub 2013 Oct 3. Expert Opin Drug Discov. 2013. PMID: 24088065 Review.
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M. Zizzari IG, et al. Among authors: gelibter a. Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26. Cancer Immunol Res. 2018. PMID: 29700053
Coexistence of three EGFR mutations in an NSCLC patient: A brief report.
Belardinilli F, Gradilone A, Gelibter A, Zani M, Occhipinti M, Ferraro S, Nicolazzo C, Coppa A, Giannini G. Belardinilli F, et al. Among authors: gelibter a. Int J Biol Markers. 2018 Jun 1:1724600818782200. doi: 10.1177/1724600818782200. Online ahead of print. Int J Biol Markers. 2018. PMID: 29945477 Free article.
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F. Grossi F, et al. Among authors: gelibter a. Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13. Eur J Cancer. 2018. PMID: 30014881
114 results